FDA refuses to review Moderna's mRNA flu vaccine
sklargh Wednesday, February 11, 2026
Summary
The FDA has refused to review Moderna's mRNA-based flu vaccine, citing a lack of safety data and concerns about the vaccine's potential side effects. This decision highlights the ongoing regulatory challenges faced by mRNA technology in the development of new vaccines.
11
0
Summary
arstechnica.com